<div id="readability-page-1"><p>Garland Capital Management Inc. trimmed its holdings in shares of  AbbVie Inc. (NYSE:ABBV - Free Report) by 76.7% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 2,160 shares of the company's stock after selling 7,123 shares during the quarter. AbbVie makes up  about  6.9% of Garland Capital Management Inc.'s investment portfolio, making the stock its 3rd largest holding. Garland Capital Management Inc.'s holdings in AbbVie were worth $500,000 as of its most recent SEC filing.</p><ul><li>AbbVie’s Prognosis: The February Dip Looks Like a Buy Signal</li></ul><p>A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Ellenbecker Investment Group raised its holdings in  AbbVie by 0.8% in the 3rd quarter. Ellenbecker Investment Group now owns 5,334 shares of the company's stock worth $1,235,000 after purchasing an additional 44 shares during the period.  Security National Bank of Sioux City Iowa IA raised its stake in shares of  AbbVie by 0.3% in the third quarter. Security National Bank of Sioux City Iowa IA now owns 15,382 shares of the company's stock worth $3,562,000 after buying an additional 45 shares during the period.  Matthew Goff Investment Advisor LLC lifted its position in shares of  AbbVie by 0.3% during the 3rd quarter. Matthew Goff Investment Advisor LLC now owns 17,561 shares of the company's stock valued at $4,066,000 after buying an additional 45 shares in the last quarter.  Centennial Wealth Advisory LLC grew its stake in shares of  AbbVie by 2.2% during the 3rd quarter. Centennial Wealth Advisory LLC now owns 2,089 shares of the company's stock valued at $484,000 after acquiring an additional 45 shares during the period.  Finally, Willner &amp; Heller LLC increased its holdings in  AbbVie by 0.6% in the 3rd quarter. Willner &amp; Heller LLC now owns 7,596 shares of the company's stock worth $1,759,000 after acquiring an additional 46 shares in the last quarter. 70.23% of the stock is owned by hedge funds and other institutional investors. </p><h2>Key AbbVie News</h2><p>Here are the key news stories impacting AbbVie this week:</p><ul>   <li><span>Positive Sentiment: </span>Morgan Stanley raised its price target to $270 and kept an &#34;overweight&#34; call, signaling institutional analyst conviction that AbbVie has double‑digit upside from current levels. Read More.</li>    <li><span>Positive Sentiment: </span>Company forecasts for full‑year 2026 profit came in above estimates, driven by strong sales of newer immunology drugs (Skyrizi, Rinvoq), supporting the case for continued top‑line and earnings growth. Read More.</li>    <li><span>Positive Sentiment: </span>Market commentary and some analysts view the post‑earnings pullback as a buying opportunity, pointing to institutional accumulation, durable cash flow, and a strong dividend as anchors for medium‑term returns. Read More.</li>    <li><span>Positive Sentiment: </span>New real‑world Rinvoq data from Japan bolsters the drug's addressable market for ankylosing spondylitis and reinforces growth prospects for AbbVie’s immunology franchise. Read More.</li>    <li><span>Neutral Sentiment: </span>Management framed the earnings call around &#34;new growth engines&#34; — Skyrizi/Rinvoq and other launches taking the lead in driving growth, which supports the long‑term story but doesn't eliminate near‑term volatility. Read More.</li>    <li><span>Neutral Sentiment: </span>Q4 results beat on revenue and showed strong margin/earnings leverage, confirming product momentum even as some segments face headwinds. Read More.</li>    <li><span>Negative Sentiment: </span>Shares initially gapped down after the print as investors focused on a softer-than‑expected Q1 EPS and revenue outlook despite the quarter’s beats — a classic near‑term reaction to guidance misses. Read More.</li>    <li><span>Negative Sentiment: </span>AbbVie set Q1 2026 EPS guidance at $2.97–$3.01 (vs. ~3.11 consensus) and gave revenue guidance below the street, creating short‑term uncertainty about the cadence of 2026 growth. Read More.</li>    <li><span>Negative Sentiment: </span>Broader coverage highlighted investor &#34;angst&#34; and a bifurcated reaction — bullish on medium‑term fundamentals but worried about near‑term comps and valuation — keeping volatility elevated. Read More.</li> </ul><h2>AbbVie Stock Up 2.0%</h2><ul><li>3 “Forever Stocks” to Hold When the Market Won’t Sit Still</li></ul><p>Shares of ABBV stock opened at $223.50 on Friday. The company's fifty day simple moving average is $223.74 and its two-hundred day simple moving average is $219.41. AbbVie Inc. has a 52 week low of $164.39 and a 52 week high of $244.81. The stock has a market cap of $395.01 billion, a P/E ratio of 94.70, a PEG ratio of 0.89 and a beta of 0.35. </p><p>AbbVie (NYSE:ABBV - Get Free Report) last issued its quarterly earnings data on Wednesday, February 4th. The company reported $2.71 earnings per share for the quarter, beating analysts' consensus estimates of $2.65 by $0.06. The firm had revenue of $16.62 billion during the quarter, compared to analyst estimates of $16.39 billion. AbbVie had a negative return on equity of 4,184.47% and a net margin of 6.91%.The business's quarterly revenue was up 10.0% compared to the same quarter last year. During the same quarter last year, the business posted $2.16 earnings per share. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS.  On average, analysts anticipate that  AbbVie Inc. will post 12.31 EPS for the current fiscal year. </p><h2>Wall Street Analyst Weigh In</h2><ul><li>AbbVie Call Options Spike 2,599%: Tracking the Big Bet</li></ul><p>Several equities analysts have weighed in on the stock. Sanford C. Bernstein  reaffirmed a &#34;market perform&#34; rating on shares of AbbVie in a report on Thursday. Wall Street Zen downgraded shares of AbbVie from a &#34;strong-buy&#34; rating to a &#34;buy&#34; rating in a report on Saturday, January 3rd. Guggenheim increased their price target on AbbVie from $227.00 to $242.00 and gave the stock a &#34;buy&#34; rating in a research note on Monday, October 20th. Evercore lowered their price objective on AbbVie from $232.00 to $228.00 and set an &#34;outperform&#34; rating on the stock in a research report on Wednesday. Finally, Morgan Stanley upped their price objective on AbbVie from $269.00 to $270.00 and gave the stock an &#34;overweight&#34; rating in a research note on Thursday. Two investment analysts have rated the stock with a Strong Buy rating, eleven have assigned  a Buy rating and nine have given a Hold rating to the stock. Based on data from MarketBeat, the stock  has an average rating of &#34;Moderate Buy&#34; and an average price target of $251.00.</p><p><b>Read Our Latest Stock Analysis on AbbVie</b></p><h2>About AbbVie</h2> (Free Report)<p>AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.  </p><p>AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than AbbVie</li><li>NEW LAW: Congress Approves Setup For Digital Dollar?</li><li>The day the gold market broke</li><li>What a Former CIA Agent Knows About the Coming Collapse</li><li>Your Bank Account Is No Longer Safe</li><li>He just nailed another gold prediction …</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCQlY?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCQlY"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in AbbVie Right Now?</h2><p>Before you consider AbbVie, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbbVie wasn't on the list.</p><p>While AbbVie currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

SBIO

<p>Garland Capital Management Inc. reduced its stake in AbbVie Inc. by 76.7% in Q3, now holding 2,160 shares valued at $500,000. Other institutional investors have also adjusted their positions in AbbVie. Despite mixed sentiments surrounding AbbVie’s recent earnings and guidance, analysts remain optimistic about its growth potential, particularly due to strong sales of newer immunology drugs. AbbVie’s stock is currently trading at $223.50, with a market cap of $395.01 billion and a P/E ratio of 94.70.</p>

Market Beat

Proshares Ultra Nasdaq Biotech

VG Health

ALPS Medical Breakthrough

Abbvie

SPDR S&P Biotech

iShares Biotechnology ETF

Invesco Biotechnology & Genome ETF

VanEck Biotech ETF

Health Care Select Sector SPDR

Ark Genomic Revolution ETF

iShares US Pharma

First Trust NYSE Arca Biotech Index Fd

Invesco Nasdaq Biotechnology ETF

Garland Capital Management Inc. Lowers Stake in AbbVie Inc. $ABBV